Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1971 2
1972 4
1973 2
1974 1
1975 2
1976 4
1977 2
1978 2
1979 4
1980 2
1981 2
1982 6
1985 4
1986 1
1987 1
1990 3
1992 1
1993 1
1996 1
1999 2
2001 3
2003 1
2006 2
2007 1
2008 1
2010 1
2011 1
2012 2
2013 1
2015 1
2017 1
2018 2
2019 1
2020 4
2021 5
2022 2
2023 1
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH; SIMPLIFY Study Group. Mayer-Hamblett N, et al. Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4. Lancet Respir Med. 2023. PMID: 36343646 Free PMC article. Clinical Trial.
Allopurinol-mercaptopurine interaction.
Weissman AM, Christian DG, Cornelis WA, Fortner CL. Weissman AM, et al. Among authors: fortner cl. J Am Pharm Assoc. 1973 Jan;13(1):2. J Am Pharm Assoc. 1973. PMID: 4682571 No abstract available.
Carcinoma of the breast.
Grove WR, Fortner CL. Grove WR, et al. Among authors: fortner cl. J Am Pharm Assoc. 1976 May;16(5):254-62. doi: 10.1016/s0003-0465(16)33571-6. J Am Pharm Assoc. 1976. PMID: 774002 Review. No abstract available.
Advances in oncology pharmacy practice.
Shank BR, Schwartz RN, Fortner C, Finley RS. Shank BR, et al. Among authors: fortner c. Am J Health Syst Pharm. 2015 Dec 1;72(23):2098-100. doi: 10.2146/ajhp150637. Am J Health Syst Pharm. 2015. PMID: 26581937 No abstract available.
High-dose methotrexate with folinic acid rescue.
Bender JF, Grove WR, Fortner CL. Bender JF, et al. Among authors: fortner cl. Am J Hosp Pharm. 1977 Sep;34(9):961-5. Am J Hosp Pharm. 1977. PMID: 333910 Review.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
80 results